Lead Sponsor

Yonsei University

Age

4 - 16 years

Sex

ALL

Healthy Volunteers

No

•1. Patients from age 4 to 16, who have been diagnosed with focal epilepsy
•2. Patients who have experienced minimal two unprovoked seizures, or patients who have had one unprovoked seizure and have shown focal abnormality in the EEG
•3. Patients who have not received any antiepileptic medications prior to the study (Those who have been treated with rescue medication are eligible)
•4. Patients with eligible consent or with legal guardians have given official consent

•1. Patients with progressive CNS disease, or systemic illness
•2. Patients with level of SGOT/SPGT above the doubled normal level or BUN/Creatinine above the 3 times of the normal range
•3. Patients who had used other anti-epileptic medication during any period of the trial, including baseline period. (Benzodiazepine used as rescue therapy is acceptable)
•4. Patients who show hypersensitive reaction to the study medication.
•5. Patients with any psychological problems.
•6. Patients deemed inappropriate for the study by the investigators

Related studies

NCT07505004 · Focal Epilepsy

NCT07219407 · Focal Epilepsy, Epilepsy, and more

NCT06205160 · Focal Epilepsy, Intraoperative Monitoring

NCT07238868 · Focal Epilepsy

NCT06716801 · Focal Epilepsy With and Without Secondary Generalization

The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study